Guided Therapeutics (GTHP) Income towards Parent Company (2016 - 2025)
Guided Therapeutics' Income towards Parent Company history spans 16 years, with the latest figure at -$1.2 million for Q4 2025.
- On a quarterly basis, Income towards Parent Company fell 86.81% to -$1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.2 million, a 32.31% decrease, with the full-year FY2025 number at -$3.2 million, down 32.23% from a year prior.
- Income towards Parent Company hit -$1.2 million in Q4 2025 for Guided Therapeutics, down from -$742000.0 in the prior quarter.
- Over the last five years, Income towards Parent Company for GTHP hit a ceiling of $68000.0 in Q3 2021 and a floor of -$1.8 million in Q4 2022.
- Historically, Income towards Parent Company has averaged -$768650.0 across 5 years, with a median of -$693000.0 in 2023.
- Biggest five-year swings in Income towards Parent Company: skyrocketed 84.68% in 2021 and later tumbled 1720.59% in 2022.
- Tracing GTHP's Income towards Parent Company over 5 years: stood at -$444000.0 in 2021, then crashed by 306.98% to -$1.8 million in 2022, then soared by 78.64% to -$386000.0 in 2023, then plummeted by 68.91% to -$652000.0 in 2024, then crashed by 86.81% to -$1.2 million in 2025.
- Business Quant data shows Income towards Parent Company for GTHP at -$1.2 million in Q4 2025, -$742000.0 in Q3 2025, and -$811000.0 in Q2 2025.